{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T21:28:54Z","timestamp":1668634134106},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T00:00:00Z","timestamp":1540598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Xuan Zhu Pharma Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40261-018-0722-5","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T04:10:09Z","timestamp":1540613409000},"page":"85-96","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L\/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects"],"prefix":"10.1007","volume":"39","author":[{"given":"Sufeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,27]]},"reference":[{"key":"722_CR1","first-page":"309","volume":"11","author":"BL Chen","year":"2015","unstructured":"Chen BL, Zhang YZ, Luo JQ, Zhang W. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag. 2015;11:309\u201317.","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"722_CR2","doi-asserted-by":"publisher","first-page":"e48255","DOI":"10.1371\/journal.pone.0048255","volume":"7","author":"RV Picon","year":"2012","unstructured":"Picon RV, Fuchs FD, Moreira LB, Riegel G, Fuchs SC. Trends in prevalence of hypertension in brazil: a systematic review with meta-analysis. PLoS One. 2012;7(10):e48255.","journal-title":"PLoS One"},{"key":"722_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40885-016-0042-0","volume":"22","author":"N Jarari","year":"2015","unstructured":"Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, Nelapalli NK, Min Y, Tun KD, Jamallulail SI, Rawal AK, Ramanujam R, Yedla RN, Kandregula DK, Argi A, Peela LT. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens. 2015;22:7.","journal-title":"Clin Hypertens."},{"key":"722_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/00003495-200565002-00005","volume":"65","author":"RR Wenzel","year":"2005","unstructured":"Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs. 2005;65:29\u201339.","journal-title":"Drugs."},{"key":"722_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1381612820666141024151119","volume":"21","author":"A Zisaki","year":"2015","unstructured":"Zisaki A, Miskovic L, Hatzimanikatis V. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des. 2015;21:806\u201322.","journal-title":"Curr Pharm Des"},{"key":"722_CR6","first-page":"67","volume":"14","author":"AL Wang","year":"2017","unstructured":"Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol. 2017;14:67\u201372.","journal-title":"J Geriatr Cardiol."},{"key":"722_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/jhh.2014.79","volume":"29","author":"J Dingemanse","year":"2015","unstructured":"Dingemanse J, Otasevic P, Shakeri-Nejad K, Klainman E, Putnikovic B, Kracker H, Mueller MS, Zimlichman R. Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension. J Hum Hypertens. 2015;29:229\u201335.","journal-title":"J Hum Hypertens"},{"key":"722_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0014-2999(98)00204-0","volume":"349","author":"H Masumiya","year":"1998","unstructured":"Masumiya H, Shijuku T, Tanaka H, Shigenobu K. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol. 1998;349:351\u20137.","journal-title":"Eur J Pharmacol"},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1291\/hypres.30.797","volume":"30","author":"M Ohishi","year":"2007","unstructured":"Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res. 2007;30:797\u2013806.","journal-title":"Hypertens Res"},{"key":"722_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0006-8993(98)01018-X","volume":"813","author":"H Ishibashi","year":"1998","unstructured":"Ishibashi H, Murai Y, Akaike N. Effect of nilvadipine on the voltage-dependent Ca2+ channels in rat hippocampal CA1 pyramidal neurons. Brain Res. 1998;813:121\u20137.","journal-title":"Brain Res"},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4070\/kcj.2010.40.10.514","volume":"40","author":"IY Oh","year":"2010","unstructured":"Oh IY, Seo MK, Lee HY, Kim SG, Kim KS, Kim WH, Hyon MS, Han KR, Lim SJ, Kim CH. Beneficial effect of efonidipine, an L- and T-type dual calcium channel blocker, on heart rate and blood pressure in patients with mild-to-moderate essential hypertension. Korean Circ J. 2010;40:514\u20139.","journal-title":"Korean Circ J."},{"key":"722_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1161\/01.RES.0000256155.31133.49","volume":"100","author":"K Hayashi","year":"2007","unstructured":"Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100:342\u201353.","journal-title":"Circ Res"},{"key":"722_CR13","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/hr.2011.74","volume":"34","author":"K Hayashi","year":"2011","unstructured":"Hayashi K. L-\/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers. Hypertens Res. 2011;34:910\u20132.","journal-title":"Hypertens Res"},{"key":"722_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1152\/ajpregu.00276.2014","volume":"308","author":"PB Hansen","year":"2015","unstructured":"Hansen PB. Functional importance of T-type voltage-gated calcium channels in the cardiovascular and renal system -news from the world of knock-out mice. Am J Physiol Regul Integr Comp Physiol. 2015;308:227\u201337.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"722_CR15","first-page":"1","volume":"28","author":"S Zhou","year":"2018","unstructured":"Zhou S, Tao M, Wang Y, Lu W, Xie L, Chen J, Zhao Y, Yun L, Zhang H, Ning O. Effects of CYP3A4*1G and CYP3A5*3 Polymorphisms on Pharmacokinetics of Tylerdipine hydrochloride in Healthy Chinese Subjects. Xenobiotica. 2018;28:1\u20136.","journal-title":"Xenobiotica"},{"key":"722_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/j.1552-4604.1995.tb04117.x","volume":"35","author":"H Boxenbaum","year":"1995","unstructured":"Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35:763\u20136.","journal-title":"J Clin Pharmacol"},{"key":"722_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3109\/00498254.2016.1156185","volume":"46","author":"H Wang","year":"2016","unstructured":"Wang H, Ou N, Lang L, Shi R, Hu P, Jiang J. Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses. Xenobiotica. 2016;46:1133\u201341.","journal-title":"Xenobiotica"},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.clinthera.2009.04.013","volume":"31","author":"MY Liu","year":"2009","unstructured":"Liu MY, Jingying Jia M, Gangyi Liu M, Li S, Chuan LuB, Yanmei Liu M, Yu MC. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: An open-label, single-dose, randomized, two-way crossover study in healthy chinese male volunteers. Clin Ther. 2009;31:777\u201383.","journal-title":"Clin Ther"},{"key":"722_CR19","unstructured":"US Food and Drug Administration. Safety testing of drug metabolites guidance for industry. 2016. \n                    http:\/\/www.fda.gov\/downloads\/drugs\/guidancecompliance\n                    \n                   regulatoryinformation\/guidances\/ucm079266.pdf. Accessed 22 Nov 2016."},{"key":"722_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s13318-014-0197-6","volume":"40","author":"J Jiang","year":"2015","unstructured":"Jiang J, Li L, Yin H, Woessner R, Emotte C, Li R, Khindri S, Pei H. Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2015;40:203\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0722-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T23:25:47Z","timestamp":1572132347000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0722-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0722-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,27]]},"assertion":[{"value":"27 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Xuan Zhu Pharma Co., Ltd. (Jinan, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no potential conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The studies were approved by the Ethics Committee of the First Affiliated Hospital with Nanjing Medical University (Nanjing, China) and the approval numbers are 2014-MD-164.A1 for SAD study and 2015-MD-141 for MAD study, respectively.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}